The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London midday: Stocks bounce back after recent sell-off

Tue, 28th May 2013 11:20

UK markets were registering impressive gains on Tuesday morning with hopes of continued monetary easing in the Eurozone lifting sentiment as stocks bounced back following last week's sharp sell-off.After reaching a 13-year high on Wednesday, the FTSE 100 dropped sharply in the latter part of last week - losing nearly 3.0% in just two days - on fears of a scaling back of stimulus measures from the US Federal Reserve as well as some gloomy economic data from China.However with UK and US markets closed for national holidays on Monday, traders were looking to play catch up after missing out on the previous day's rally. Helping the bullish mood today were comments from European Central Bank (ECB) board member Peter Praet who said that the bank could still cut interest rates if needed to support the economy. In recent interviews, Praet said that "even after cutting the cost of money to a record low of 0.50%, the ECB signalled that the possibility of further easing was not exhausted".Market Analyst Craig Erlam from Alpari said: "Investor sentiment is on the rise in Europe this morning, with stock indices following in the footsteps of their Asian counterparts over night, which recovered early losses to end the session higher." Tuesday's session was the first positive day on Tokyo's Nikkei index since it dropped by 7.3% on Thursday."Now that the dust is beginning to settle, we could be seeing traders take advantage of the dip in the market to buy on the cheap. Given that the Bank of Japan's massive bond buying programme is only just getting under way, I think this will be the case," Erlam said.The economic data calendar was on the light side on Tuesday morning in Europe, though eyes will be fixed on consumer confidence and home-price figures in the States due out this afternoon.FTSE 100: TUI Travel, pharmas and banks provide a liftTour operator TUI Travel was among the best performers this morning, rising in sympathy with French peer Club Mediterranee after its shareholders Fosun International and Axa Private Equity joined forces to make a €540m bid for the firm.Drugs giant AstraZeneca higher after saying that it will continue to "vigorously" defend the intellectual property rights protecting its asthma medicine Pulmicort Respules. The company is appealing against a US court ruling that the patent protecting Pulmicort from rival drugs in the US is invalid. Sector peers Shire and GlaxoSmithKline were also in demand early on, with the latter being boosted by an upgrade by Deutsche Bank to 'buy'.Financial stocks were also performing well as markets on the whole rebounded from last week's sell-off. HSBC, Barclays and Standard Chartered were in positive territory, joined by part-nationalised lenders RBS and Lloyds which were both shrugging off downgrades by Citigroup today.Wood Group was also higher on news that its PSN business will continue to provide duty holder and asset management services to the Hummingbird Spirit floating storage offloading production vessel, under a new contract extension worth $87m from Teekay. Positive comments from Bank of America Merrill Lynch were helping share prices of a number of retailers this morning after the broker raised its target prices for Sainsbury, Marks & Spencer and Tesco.FTSE 250: Victrex jumps after first-half reportPolymer manufacturer Victrex was a high riser on the second-tier index after increasing its interim dividend by 15% despite a slight fall in profits. The company however still managed to beat profit before tax forecasts by 2.0% in the first half.Soft drinks maker AG Barr was also up as it managed to increase revenues by 2.4% in the first quarter in spite of the dismal weather.Mining firm Kazakhmys was heading the other way after announcing that it has sold its long-held German copper products unit MKM for €42m. "MKM is an excellent business, but did not fit with our geographic and strategic focus as a natural resources company in Central Asia," the company said.FTSE 100 - RisersPetrofac Ltd. (PFC) 1,391.00p +3.81%Barclays (BARC) 328.95p +3.77%TUI Travel (TT.) 371.50p +3.63%CRH (CRH) 1,438.00p +3.45%Weir Group (WEIR) 2,373.00p +3.40%Melrose Industries (MRO) 263.70p +3.33%GKN (GKN) 305.90p +3.21%International Consolidated Airlines Group SA (CDI) (IAG) 281.60p +3.15%Babcock International Group (BAB) 1,202.00p +3.09%AstraZeneca (AZN) 3,534.00p +3.09%FTSE 100 - FallersEurasian Natural Resources Corp. (ENRC) 249.00p -2.28%Randgold Resources Ltd. (RRS) 4,921.00p -1.34%Severn Trent (SVT) 2,049.00p -1.06%Anglo American (AAL) 1,549.00p -0.48%United Utilities Group (UU.) 784.00p -0.38%Carnival (CCL) 2,229.00p -0.36%Glencore Xstrata (GLEN) 331.75p -0.03%Rio Tinto (RIO) 2,866.50p -0.02%FTSE 250 - RisersNew World Resources A Shares (NWR) 115.20p +8.88%Victrex (VCT) 1,720.00p +5.65%Pace (PIC) 260.00p +4.00%Ferrexpo (FXPO) 177.20p +3.99%Telecity Group (TCY) 979.50p +3.93%Laird (LRD) 212.10p +3.87%Inchcape (INCH) 569.50p +3.73%Ashtead Group (AHT) 655.00p +3.39%Spirax-Sarco Engineering (SPX) 2,881.00p +3.37%Homeserve (HSV) 263.60p +3.37%FTSE 250 - FallersHochschild Mining (HOC) 241.30p -2.43%Kazakhmys (KAZ) 318.40p -2.36%AZ Electronic Materials SA (DI) (AZEM) 316.30p -2.23%Kenmare Resources (KMR) 31.00p -2.08%Dunelm Group (DNLM) 854.00p -1.84%EnQuest (ENQ) 131.50p -1.28%Telecom Plus (TEP) 1,271.00p -1.24%Salamander Energy (SMDR) 164.80p -1.20%HICL Infrastructure Company Ltd (HICL) 128.60p -1.08%Carpetright (CPR) 635.00p -1.01%
More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.